Latest News

DRDGOLD is progressing its Vision 2028 initiative, focused on infrastructure upgrades and operational improvements across its tailings operations. The company is moving ahead with plans to link processing plants and restart deposition at key tailings storage facilities. These developments are intended to support longer term operating plans and more efficient use of existing assets. For investors watching NYSE:DRD, the Vision 2028 work sits against a share price of $38.32 and multi year...

Multiple law firms have filed class action lawsuits against Richtech Robotics (NasdaqCM:RR) alleging the company misled investors about its relationship with Microsoft. The suits claim Richtech described a collaborative and commercial partnership with Microsoft, while Microsoft has reportedly denied having a commercial relationship. Investors are focusing on potential disclosure issues, legal exposure, and the impact of these claims on Richtech's credibility and future capital...

Carter's (NYSE:CRI) has reported its first year over year revenue growth since 2021, supported by stronger retail sales and demand creation efforts. The company plans to close about 150 lower margin stores by 2028 while expanding higher priced product assortments for Gen Z and Millennial families. Carter's is also putting more emphasis on direct to consumer channels as it adjusts to changing shopping habits and cost pressures. Carter's shares recently closed at $34.95, with the stock down...

If you are wondering whether Neo Performance Materials at around $27.61 offers real value or is running ahead of itself, you are not alone. The stock has moved sharply, with returns of 19.5% over 7 days, 44.1% over 30 days, 63.5% year to date, 274.6% over 1 year, 209.1% over 3 years and 83.8% over 5 years. Recent news coverage around Neo Performance Materials has focused on the company as part of the broader rare earth and advanced materials space. This area often attracts attention when...

Carlsberg has confirmed it is considering an IPO of its India business. The company publicly acknowledged ongoing speculation around the India listing plans. The potential IPO would give investors a direct way to gain exposure to Carlsberg’s India operations. For investors watching CPSE:CARL B, the confirmation around a possible India IPO comes at a time when the shares trade at DKK969.2. The stock is up 13.6% over the past 30 days and 17.4% year to date, with a 12.3% return over 5 years...

Telefónica, through its nexfibre joint venture, announced the acquisition of UK fibre provider Substantial Group, aiming to expand fibre infrastructure in the UK. Telefónica Spain is adopting Red Hat OpenShift to modernize and unify IT and network functions across its operations. The company, listed as BME:TEF, last closed at €3.724. For investors watching BME:TEF, these moves come as the stock trades at €3.724, with a 9.0% return over the past 30 days and a 7.0% return year to date. The...

If you are wondering whether Supernus Pharmaceuticals at around US$55.09 is still offering value after its recent run, you are not alone. The stock has posted returns of 8.7% over the past 7 days, 14.4% over 30 days, 11.4% year to date and 73.6% over 1 year, with longer term returns of 43.5% over 3 years and 116.0% over 5 years. These moves sit against a backdrop of continuing interest in Supernus Pharmaceuticals as a neurology focused drug maker. Investors are paying close attention to how...

If you are wondering whether Seatrium’s current share price really reflects its underlying value, you are not alone. This piece is built to help you frame that question clearly. Over the past week the stock shows a 4.4% return, with 30 day, year to date and 1 year returns of 11.4%, 8.3% and 12.8% respectively. The 5 year return stands at a 17.1% decline and the 3 year return at 6.7%. Recent coverage has focused on Seatrium’s role in the capital goods sector and how investors are reading its...

If you are looking at Medical Properties Trust and wondering whether the current share price reflects its underlying worth, you are not alone. The stock closed at US$5.65 recently, with returns of 12.5% over the last 30 days, 11.2% year to date and 4.4% over the past year, set against longer term 3 year and 5 year returns of 28.9% and 60.3% declines. Recent headlines around Medical Properties Trust have focused on its balance sheet, portfolio repositioning and how it is responding to a...

Winnebago Industries (NYSE:WGO) is working through persistent RV industry headwinds as sales have fallen over the past two years. Despite reporting revenue growth, the company has seen profitability weaken, pointing to rising pressure on its core business. This combination of softer sales trends and thinner margins is drawing attention to deeper challenges across the recreational vehicle sector. For you as an investor, Winnebago sits at the intersection of discretionary spending and outdoor...

If you are wondering whether Münchener Rückversicherungs-Gesellschaft in München is offering fair value at current levels, starting with a clear view of its valuation can help you frame your next move. The share price recently closed at €551.80, with returns of 1.7% over the last 7 days, 7.7% over the last 30 days, 2.1% year to date, 1.6% over 1 year, 85.0% over 3 years and 151.7% over 5 years. This gives useful context before comparing price to fundamentals. Recent news around large...

Aardvark Therapeutics recently voluntarily paused its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi Syndrome, and no longer expects to report topline data in the third quarter of 2026, with updated guidance now planned for the second quarter of 2026. The pause affects Aardvark’s lead asset in a rare disease setting where ARD-101 already holds both Orphan Drug and Rare Pediatric Disease designations from the FDA. We will now examine how the pause of the HERO Phase 3 trial for...

If you are wondering whether Enpro's current share price really reflects its underlying worth, this article walks through what the numbers actually say about value. Enpro's share price recently closed at US$264.05, with returns of 10.6% over 30 days, 20.5% year to date, 49.2% over 1 year, 155.4% over 3 years and 205.4% over 5 years. These figures may catch the eye of investors thinking about future risk and reward. Recent coverage around Enpro has focused on its role within the capital goods...

UFP Technologies (NasdaqCM:UFPT) amended its manufacturing supply agreement with Intuitive Surgical. The amendment extends the term of the partnership between the two companies. Minimum volume commitments under the agreement were increased. A new program for additional products was added to the supply arrangement. For you as an investor, this centers on UFP Technologies' role as a specialized manufacturer for the medical device sector, supplying components and solutions to a leading global...

Naturgy Energy Group, S.A. has released its full-year 2025 results, reporting sales of €19,455 million and net income of €2,023 million, both higher than the prior year. This combination of slightly higher revenue and improved profitability highlights Naturgy’s ability to lift earnings even with relatively stable topline performance. We’ll now examine how this increase in full-year sales and net income could influence Naturgy’s existing investment narrative and risk balance. The future of...

Exzeo Group has entered into a new partnership with Tokio Marine Highland to distribute TMH2O residential flood insurance. The collaboration expands Exzeo’s property insurance offerings and supports its ambitions as a multi-line, technology driven platform. For investors tracking NYSE:XZO, this announcement comes as the stock trades at $16.1, with a 3.7% gain over the past week and a 20.8% decline over the past month. Year to date, shares show a 29.3% decline, so this move may stand out as...

Earnings trigger and why Neuren is on radar Neuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net income of A$30.44 million, both lower than the prior year. See our latest analysis for Neuren Pharmaceuticals. The share price reaction has been sharp, with a 1 day share price return of an 8.79% decline and a 30 day share price return of a 24.75% decline. The 1 year total shareholder return of 1.87% and 3...

U.S. Gold Corp. recently presented at the Emerging Growth Virtual Conference on February 25, 2026, with Executive Chairman Luke Anthony Norman addressing investors. This appearance gave the company a platform to highlight its latest corporate developments and project plans directly to a broad investment audience. We’ll now explore how U.S. Gold Corp.’s Emerging Growth Virtual Conference presentation could shape its investment narrative and investor expectations. The best AI stocks today may...

Koninklijke BAM Groep nv recently reported its full-year 2025 results, with sales of €7,039.9 million and net income of €211 million, and basic earnings per share from continuing operations of €0.81, all higher than the prior year. The sharp rise in net income compared with the previous year highlights how improved profitability has amplified the impact of relatively modest top-line growth. We’ll now examine how this strong jump in net income and earnings per share may influence Koninklijke...

Per Aarsleff Holding A/S reported first-quarter 2025/26 results with sales rising to DKK 6,180 million and net income reaching DKK 187 million, modestly above the prior year. Separately, PURIS announced that PAA will become a part owner in a new LiquiForce partnership, extending Per Aarsleff’s technical footprint in Canadian infrastructure rehabilitation through shared LED-light curing and lateral renewal solutions. We’ll now examine how Per Aarsleff’s higher quarterly earnings and...

TORM plc recently reported full-year 2025 results showing sales of US$1.34 billion and net income of US$285.3 million, alongside new 2026 TCE earnings guidance of US$850 million to US$1.25 billion. The board also approved a Q4 2025 interim dividend of US$0.70 per share, highlighting management’s willingness to return substantial cash to shareholders even as earnings moderated year over year. With this combination of firm 2026 TCE guidance and a sizeable Q4 dividend, we’ll now examine how the...

Why 1911 Gold’s New Credit Facility Matters 1911 Gold (TSXV:AUMB) has drawn fresh attention after securing a $30,000,000 credit facility from Auramet International Inc., intended to fund equipment purchases, underground development, and mill upgrades at the True North Gold Project. The financing is structured in two equal tranches of $15,000,000. The second tranche is available between month three and month six after closing and carries a 12% annual interest rate, paid monthly. For investors,...

Why Sabre stock is drawing fresh attention after its latest earnings Sabre (SABR) has moved back into the spotlight after reporting fourth quarter and full year 2025 results that shifted the company from a net loss to positive net income for the year. For investors tracking travel technology names, that change in profitability and earnings per share, alongside ongoing quarterly losses, raises fresh questions about how to weigh Sabre’s recent performance against its longer term return...

Telix Pharmaceuticals (ASX:TLX) has entered an AI research collaboration with University Hospital Essen focused on PSMA-PET imaging in prostate cancer. The partnership will use Telix’s AI tools and the PROMISE-PET registry to build prognostic models for prostate cancer imaging. Telix has also submitted a European marketing authorization application for TLX101-Px, an advanced glioma imaging candidate. The glioma submission aims to address the need for more consistent, high-quality brain...